Cencora saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 70 to 78.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest climbs. See if Cencora can continue to show renewed price strength and clear that threshold.
Cencora is working on a flat base with a 309.35 buy point. See if the stock can break out in volume at least 40% above average. It's a later-stage pattern, and investors should be aware that those are less likely to lead to significant gains.
While sales growth fell last quarter from 10% to 9%, earnings-per-share grew 20%, up from 16% in the previous report.
Cencora holds the No. 1 rank among its peers in the Medical-Wholesale Drugs industry group. McKesson and Cardinal Health are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
